ADMG filed an NT 10-K. I'll be interested to see if this is because of a material change in the financials. I added more today. I think this presents an opportunity at these sub-$1 levels.

I see today that they filed another 10Q last week. I'll read it after the close.

I'm still very positive on the outcome for this and I have an account position to prove it. However, I'm choosing this year to focus more on my day trading and less on penny stocks. This is my last penny stock and when I'm out of it I won't trade a stock that doesn't have options.

Vitro Biopharma Announces Early 2016 Results: Increased Revenue and Expansion Activities to Fuel Growth

GOLDEN, CO / ACCESSWIRE / March 1, 2016 / Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced increased revenues during its first fiscal quarter 2016 of 143% compared to the same period in 2015, predominately due to further increased sales of its cell lines and MSC-Gro™ Brand of cell culture media products. Vitro Biopharma's cell line product sales are being driven by sales of our cancer-associated fibroblasts (CAFs). We are now adding key new products to our CAF and stem cell-derived cellular lineage product lines. Sales of MSC-Gro™ Cell Culture media for both research and clinical studies also continued to grow in early 2016 as also occurred during 2015. Our Clinical Grade MSC-Gro™ is now being used in clinical trials of osteoarthritis (OA), to a partner who requires anonymity. This product is manufactured in strict adherence to applicable GMP requirements that is a key property for its use in clinical trials. Our Clinical Grade MSC-Gro™ was qualified through extensive testing and has been used in OA clinical trials for the past year. Our Clinical Grade MSC-Gro™ is being used to expand patient-specific MSCs to obtain a sufficient amount of cells for direct injection and back-up injections into afflicted joints to induce cartilage regeneration and other regenerative effects to restore function, without requiring joint replacement. These trials are now providing evidence of safety and efficacy. Osteoarthritis is major global health issue affecting 10% of the US population at a total health care cost exceeding $40 billion per year. We anticipate additional demand for MSC-Gro™ and have plans to expand production capacity for Clinical Grade MSC-Gro™ by 5-fold during 2016.

In addition we are continuing to develop our TBI clinical trials and concussion support services. We are in discussions with centers regarding these trials and we are also gaining CLIA certification of our clinical laboratory for biomarker profiling critical to monitoring the status of concussion patients. Vitro Biopharma has previously operated a CLIA Certified clinical reference laboratory during the early 1990's. Our cell-based assay service is expanding through enhanced analytical capability in genetic expression and methylation analysis as part of our growing epigenetic analytical capability. We are also developing a new product line to provide stem cell activation using natural products. We anticipate launch of our concussion support service during spring 2016.

Dr. Jim Musick, Vitro Biopharma's president and CEO said, "We are pleased to announce our early 2016 results showing increased demand for Vitro Biopharma's products and services. We have appropriate expansion activities to support continued growth of our revenues to achieve profitable operations. Also, our financial partnership with C. Brooke Partners is now yielding additional opportunities for accelerated growth through strategic alliance and M&A opportunities. We look forward to continued expansion into stem cell therapeutic markets including support of stem cell transplantation therapy by use of our highly competitive Clinical Grade MSC-Gro™ expansion media and through use of our proprietary technology for stem cell activation therapy, especially for neurological conditions including TBI &concussion."

About Vitro Biopharma

Vitro Biopharma's (http://www.vitrobiopharma.com/) mission is "Harnessing the Power of Cells™" for the advancement of regenerative medicine to its full potential. Vitro Biopharma operates within a modern, GMP-compliant biotechnology manufacturing and R&D facility in Golden, Colorado. Vitro Biopharma manufactures and sells "Tools for Stem Cell and Drug Development™", including human mesenchymal stem cells and derivatives, the MSC-Gro™ Brand of optimized media for MSC self-renewal and lineage-specific differentiation. Our cell lines also include cancer-associated fibroblasts (CAFs) derived from lung, colorectal, ovarian, uterine and pancreatic tumors. In addition, we provide MSC-derived progenitor cells, including neural stem cells (NSCs), nephron progenitor cells (NPCs) as well as a growing line of terminally differentiated cells: cholinergic, dopaminergic and sensory neurons, osteoblasts, chondrocytes, cardiomyocytes, and renal tubular epithelial cells. A primary application of these terminally differentiated cells is cell-based assays for drug discovery and pre-clinical toxicology of drugs, drug candidates and drug combinations that may produce toxic effects on cardiac, neural or renal cells, either directly or through metabolites derived from the interaction of drugs with specific cells such as liver cells. Vitro Biopharma now provides its Clinical Grade MSC-Gro™ Media for expansion of stem cells prior to transplantation for clinical studies of osteoarthritis treatment and products for use in preliminary studies of stem cell activation therapy for ASD & autoimmunity.

Vitro Biopharma received the Frost and Sullivan Technology Innovation Leadership Award for the industry sector: Stem Cell Tools and Technology in North America, 2014.

Safe Harbor Statement

Statements herein regarding financial performance have not yet been reported to the SEC nor reviewed by the Company's auditors. Certain statements contained herein and subsequent statements made by and on behalf of the Company, whether oral or written may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward looking statements are identified by words such as "intends," "anticipates," "believes," "expects" and "hopes" and include, without limitation, statements regarding the Company's plan of business operations, product research and development activities, potential contractual arrangements, receipt of working capital, anticipated revenues and related expenditures. Factors that could cause actual results to differ materially include, among others, acceptability of the Company's products in the market place, general economic conditions, receipt of additional working capital, the overall state of the biotechnology industry and other factors set forth in the Company's filings with the Securities and Exchange Commission. Most of these factors are outside the control of the Company. Investors are cautioned not to put undue reliance on forward-looking statements. Except as otherwise required by applicable securities statutes or regulations, the Company disclaims any intent or obligation to update publicly these forward looking statements, whether as a result of new information, future events or otherwise.

CONTACT:

Dr. James Musick

Chief Executive Officer

Vitro Biopharma

(303) 999-2130 Ext. 3
E-mail: jim@vitrobiopharma.com

SOURCE: Vitro Diagnostics, Inc.

Quote from the letter: "Revenues derived from our cell lines increased by 67% during 2015 as compared to 2014. Also, sales of our cell culture media expanded by 100% in 2015 compared to 2014 due to increased demand for our research products"

It does note later that overall YOY revenues decreased 30% due largely to European conditions. However the focus on TBI treatments and the items mentioned above are likely the keys to seeing overall increased revenues in 2016.

I firmly believe that with the capital structure being what it is the focus in the TBI area will push this stock to previously unseen levels.

CEO Letter to Shareholders: 2015 RESULTS EXPAND THERAPY OPTIONS FOR CONCUSSION

GOLDEN, CO / ACCESSWIRE / November 4, 2015 /
Dear Shareholders:

Concussion and traumatic brain injury (TBI) are significant health risks that lack modern therapeutic approaches beyond physical therapy and rehabilitation. The TBI incidence in the US is 1.5 to 1.7 million new cases per year and is estimated to cost $75 billion per year in the US only. Concussion is a growing issue within professional athletes including the NFL where significant health problems are derived from football-related concussion. Military service personnel and numerous others are also significantly impacted by TBI. We began development of stem cell activation technology and products during 2014 and expanded these activities in during 2015 to include treatment of concussion. We have developed patent-pending technology for treatment of neurological conditions through the activation of stem cells residing within the body. This is a process for administration of stem cell therapeutic benefit without stem cell transplants.

During 2015 we:

- Submitted and received exemption from IND filing from the FDA for our novel therapy opening opportunities for clinical testing.

- Filed patent applications entitled "Treatment of Neurological Conditions by Stem Cell Activation" in the United States, and other countries. Our patent includes several methods of stem cell activation & transplantation of activated stem cells together with diagnostic tools to assess the extent of stem cell activation and measurement of brain regeneration processes including neurogenesis, angiogenesis, neuroprotection and reduction of cell death/inflammation.

- Expanded our medical team to administer clinical trials.

- Added in-house analytical capacity to perform advanced biomarker profiling at high levels of efficiency and accuracy. Our diagnostic procedures include quantitative assessment of the extent of injury during TBI that we are correlating with TBI outcome.

Our plans for 2016 include addition of support services to assist concussion victims including advanced diagnostics, consultation and information regarding therapeutic options related to activation of stem cells within the brain to heal concussion-related injury. Also, we intend to implement Phase I clinical trials at various centers in the US and off-shore facilities as well. There are similar opportunities for advanced treatment of autism based on our proprietary method of stem cell activation. Our early stage trials in the EU support this approach and we plan to expand testing in the US during 2016. Our proprietary method of stem cell activation has application to other neurological conditions including stroke that is also under-treated and represents a large health care burden to society.

We expanded our research products during 2015 to include a variety of cells derived from adult stem cells including neural, cardiac and renal cells as well as an expanding line of cancer-associated fibroblasts. Revenues derived from our cell lines increased by 67% during 2015 as compared to 2014. Also, sales of our cell culture media expanded by 100% in 2015 compared to 2014 due to increased demand for our research products and especially to sales of clinical grade cell culture media to an international stem cell firm that uses our MSC-Gro(TM) media to expand adipose-derived MSCs prior to autologous transplantation to treat skeletal-muscular conditions including osteoarthritis.

Our cardiac, neural cells and renal cells derived through differentiation of human MSCs have application to cell-based assays for drug discovery and toxicity. Well-characterized human cells provide a platform for relevant toxicology & drug discovery screening as compared to animal cells. Furthermore, co-culture systems including human hepatocytes extend screening to include drug metabolites as well as the drug or drug candidate itself. We have ongoing collaborations underway to expand commercial opportunities for these products.

While 2015 yielded significant development of the Company's ability to enter clinical markets, overall revenues decreased compared to 2014 by about 30% on an unaudited basis. The revenues gained from our EU partnership in 2014 diminished considerably during 2015 due primarily to decreased demand related to political unrest in eastern European.

In closing, 2015 saw further advances in the translation of our research products &technology into clinical products especially through sales of clinical grade MSC-Gro(TM) and expanded therapeutic options for concussion/TBI. Since the market size for advanced diagnostics & therapy of concussion/TBI is considerably larger than presently-targeted markets, we look forward to significantly increased revenues in 2016. We are now bringing our SEC filings current and also pursuing appropriate strategic combinations to accelerate growth.

Respectfully yours,

James R. Musick, Ph.D.
President, Chairman of the Board & CEO

About Vitro Biopharma

Vitro Biopharma's mission is "Harnessing the Power of Cells(TM)" for the advancement of regenerative medicine to its full potential. Vitro Biopharma operates within a modern, GMP-compliant biotechnology manufacturing and R&D facility in Golden, Colorado. Vitro Biopharma manufactures and sells "Tools for Stem Cell and Drug Development(TM)", including human mesenchymal stem cells and derivatives, the MSC-Gro(TM) Brand of optimized media for MSC self-renewal and lineage-specific differentiation. Our cell lines also include cancer-associated fibroblasts (CAFs) and MSC-derived progenitor cells, including neural stem cells as well as a growing line of terminally differentiated cells: alpha-motor neurons, dopaminergic neurons, osteoblasts, chondrocytes, cardiomyocytes, proximal tubular epithelial cells, etc. A key target of these terminally differentiated cells is their use in cell-based assays of pre-clinical toxicology of drugs, drug candidates and drug combinations that may produce toxic effects on cardiac, neural or renal cells either as drugs or drug metabolites derived from interaction with specific cells such as liver cells. Vitro Biopharma is developing clinical products through various partnerships that include providing its clinical grade media for expansion of stem cells prior to transplantation and preliminary studies of stem cell activation in ASD & autoimmunity in central Europe.

Vitro Biopharma received the Frost and Sullivan Technology Innovation Leadership Award for the industry sector: Stem Cell Tools and Technology in North America, 2014.

Safe Harbor Statement

Certain statements contained herein and subsequent statements made by and on behalf of the Company, whether oral or written may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward looking statements are identified by words such as "intends," "anticipates," "believes," "expects" and "hopes" and include, without limitation, statements regarding the Company's plan of business operations, product research and development activities, potential contractual arrangements, receipt of working capital, anticipated revenues and related expenditures. Factors that could cause actual results to differ materially include, among others, acceptability of the Company's products in the market place, general economic conditions, receipt of additional working capital, the overall state of the biotechnology industry and other factors set forth in the Company's filings with the Securities and Exchange Commission. Most of these factors are outside the control of the Company. Investors are cautioned not to put undue reliance on forward-looking statements. Except as otherwise required by applicable securities statutes or regulations, the Company disclaims any intent or obligation to update publicly these forward looking statements, whether as a result of new information, future events or otherwise.

CONTACT:

Dr. James Musick
Chief Executive Officer
Vitro Biopharma
(303) 999-2130 Ext. 3
E-mail: jim@vitrobiopharma.com

SOURCE: Vitro Diagnostics, Inc.

I am confident the Q's will be filed.

The recent selling, several hundred thousand shares, is from an investor who couldn't hold on due to financial necessity. They won't hurt us in the long run.

We do need to see those financials before their absence causes other problems. I am confident, however, that those efforts we don't see at this time will result in a higher price. There is a lot of value here.

Are there any active followers to this board? Does anyone have any current insights into the company? I've bought several times at this .025 level and made some quick profits. I've been buying again the last couple of days with that same .04-.05 expectation.

In the last conversation I had with Jim he indicated the financials should be out by the end of October. Apparently there is a lot to catch up; he didn't elaborate beyond that.

I keep a bid in there to get anything I can at these low prices. It's sometimes frustrating to see these algorithm games being played on stocks at this level.

This is a staggering example of the need for stem cell therapies in brain injury patients.

http://www.pbs.org/wgbh/pages/frontline/sports/concussion-watch/new-87-deceased-nfl-players-test-positive-for-brain-disease/

It is getting especially frustrating when you have an order on the bid or offer and an algorithm executes 59 (for example) shares of a 10000 share order to knock that order off the level 2. Trying to analyze why a trade happens at one price or another is a futile exercise. It is all speculation.

I think this recent FDA approval on the TBI treatment is going to move the needle. How much it moves and how fast depends on the flow of information we get from the company. Clearly just the huge amount of money the NFL is contributing to the former players shows the magnitude and the potential.

This could be one of the most promising news releases we've had from the company in quite a while. I think this because of the possibility of strong growing cash flow that could come from the many applications for this therapy. We're aware of the success by others in using stem cells to treat stroke victims. There is also a very great demand in the market of athletes and former athletes who suffer the lasting effects of concussion. The upcoming movie with Will Smith will certainly push this subject even further into the American sports conversation.

What the release did not mention is the 8-K that was filed just the day before. I expect that another release is just around the corner that will give us a little more insight into that arrangement.

GOLDEN, CO / ACCESSWIRE / September 2, 2015 / Vitro Diagnostics, Inc. (VODG), dba Vitro Biopharma, announced advances in clinical applications of its products and a favorable ruling by the FDA regarding this trial. The Company's phase I clinical trial consists of combining two previously FDA-approved drugs in a novel manner to treat TBI, including concussion, by regeneration of damaged cells through the activation of resident stem cells within the brain. TBI is a high incidence condition with few therapeutic options besides reduction of secondary injury and rehabilitation or physical therapy. Brain stem cells exist in only restricted parts of the brain but appear to be capable of regenerating cells of the brain when activated by the appropriate biological signal, in this case, a unique combination of drugs previously approved for other indications. While stem cell therapy is often achieved by stem cell transplants, it is also possible to activate stem cells by biological signaling agents that activate specific pathways resulting in stem cell proliferation, differentiation and migration. There are FDA-approved drugs used to stimulate red and white blood cell formation that have been used for decades now to treat patients undergoing chemotherapy and the resulting blood cell deficiencies. Other stem cell activating compounds are known and being developed.

The trial is mainly a test of safety of a specific drug combination in TBI patients. There is evidence from other clinical studies that this combination is safe. We requested an exemption from investigational new drug (IND) requirements from the FDA since this trial relies on previously marketed products. The FDA has reviewed our request and sent the Company notice of Acknowledgement of IND exemption for the drug combination that we will be testing. The Company plans future development of improved formulations, delivery routes and other technical attributes to assure optimal activation of stem cells within the brain. Also, this trial requires advanced measurement of brain functional status including brain imagining and use of biomarker chemistry profiling in order to insure adequate activation of stem cell function.

Dr. Jim Musick, Vitro Biopharma's President & CEO, said, "We are pleased to announce advances in our TBI clinical trial and notification from the FDA that our trial meets all requirements for exemption from IND regulations. This is a tribute to our regulatory team and should enable further trials targeting the treatment of other neurological conditions such as autism, stroke, Alzheimer's disease, etc. Our trial of TBI will also require approval by an institutional review board (IRB) prior to enrollment. However, this review process is relatively rapid and we anticipate completion of all regulatory approvals for this trial within the near future. We have advanced analytical capabilities to provide support of this trial through diagnostic assessment of stem cell activation within the brain. This work is predominantly focused on biomarker profiling of biological processes of stem cell activation that may result in restoration of neurological functioning. Imaging of brain stem cells together with advanced cognitive functional assessment and the quantitative determination of the effect of stem cell activation is an overall objective. The Company is developing a new medical device to quantify extent of injury, neurogenesis, neuroprotection, angiogenesis and anti-inflammatory/anti-apoptotic status in TBI."

About Vitro Biopharma

Vitro Biopharma's mission is "Harnessing the Power of Cells(TM)" for the advancement of regenerative medicine to its full potential. Vitro Biopharma operates within a modern, GMP-compliant biotechnology manufacturing and R&D facility in Golden, Colorado. Vitro Biopharma manufactures and sells "Tools for Stem Cell and Drug Development(TM)," including human mesenchymal stem cells and derivatives, the MSC-Gro(TM) Brand of optimized media for MSC self-renewal and lineage-specific differentiation. Our cell lines also include cancer-associated fibroblasts (CAFs) and MSC-derived progenitor cells, including neural stem cells as well as a growing line of terminally differentiated cells: alpha-motor neurons, osteoblasts, chondrocytes, cardiomyocytes, proximal tubular epithelial cells, etc. A key target of these terminally differentiated cells is their use in cell-based assays of pre-clinical toxicology of drugs, drug candidates and drug combinations that may produce toxic effects on cardiac, neural or renal cells either as drugs or drug metabolites derived from interaction with specific cells such as liver cells. Vitro Biopharma is developing clinical products through various partnerships that include providing its clinical grade media for expansion of stem cells prior to transplantation and preliminary studies of stem cell activation in ASD & autoimmunity in central Europe.

Vitro Biopharma received the Frost and Sullivan Technology Innovation Leadership Award for the industry sector: Stem Cell Tools and Technology in North America, 2014.

Dr Musick is wearing all the hats right now and does not have the best guidance on how to wear his CFO hat. The primary effort has been on the medical business. Financial matters, important of course, have unfortunately been secondary. Any areas that are behind in reporting are being addressed. It is expected that when the Q3 is filed in mid-September the Q2 will be filed with it.

More importantly there are advances being made with Vitro's product line. I do not think it will be very long before we see information about those efforts.

I have been a buyer for over a year and continue to buy on the dips. I don't buy microcaps very often. When I do I am willing to hold for a long time and for very large gains.

Thanks for noticing the picture. That is my son holding the phone and flipping quote screens on the DTN unit. Does anyone remember those? That was 1992.

Certainly the NT 10-Q should have been filed for Q2 as it was for Q1. We discussed the filings and the concerns about the lateness of them. It appears that he was not advised to file the NT 10-Q, a lapse on the part of the people who advise him on the filings.

It was very difficult to get that hour but we covered a lot of information, both operational and financial. There were a number of issues discussed but the only ones I can share here relate to the filings.

Jim was on the phone with me for over an hour this morning. The company has been very busy and solely focused on vital medical work. Information about these efforts will be released soon.

I did ask Jim's permission to share the following information about the filings. Given the importance of the medical work it was simply not possible to file Q2 on time. Q2 and Q3 should be filed together when the Q3 filing is due in mid-September.

I am excited by today's price and volume opportunity and have taken advantage of it.

It is my opinion, but I suspect the largest percentage of sales is coming from the former board member that may have tendered his 144 stock for sale. From wherever it is coming I am averaging down on my belief that the accumulation of progress is going to result in one of the most productive and profitable years in company history. I also trust the company will get the Q's filed after other important material matters are advanced.

The interview with Jed Miesner is out tonight. I listened to it on www.MoneyChannel.tv.

The opportunity to buy below .10, which I have done today, is great news. Perhaps someone read too much into the 8-K and gave in to their waning patience. I do not think this selling is directly related to the 8-K. I'm a buyer.

Amazing Energy Oil & Gas Co. announces record sales in the month of February, 2015

3/27/15, 08:00
SPOKANE, Wash.--(BUSINESS WIRE)-- Terry Dunne, Chairman and CEO of Amazing Energy Oil & Gas Co. ("AMAZ" on the OTCBB) is pleased to announce The Company has sold a record number of barrels of oil in the month of February, 2015. Mr. Dunne stated that, "We are very excited with the progress of our production as we continue to build out our drilling program with plans of expanding drilling operations into adjacent sections soon. The Company has signed a formal LOI with an aggressive oil and gas exploration and production company to joint venture on defined sections of the leasehold, and is working to execute a definitive agreement. We expect to spud a new well within the next sixty days, with or without an agreement."

Amazing Energy Oil and Gas Co. is active in Pecos County Texas, which is in the Permian Basin. The Company's leasehold continues to be very attractive with multiple pay zones. This is a conventional drilling project, in a proven produced area. The White & Baker and Walker fields being just north and east of the current drill sites have produced approximately 15 million barrels of oil. Mr. Dunne went on to say, "The Yates field just east of the approximate 70,000 acre leasehold has produced over a billion barrels of oil to date."

Please also reference our website at amazingenergy.com.

This Press Release contains certain forward-looking statements and our future operating results could differ materially from those discussed herein. Certain statements contained in this Report, including, without limitation, statements containing the words "believes," "anticipates," "expects" and the like, constitute "forward-looking statements". Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such factors or to announce publicly the results of any revisions of the forward-looking statements contained or incorporated by reference herein to reflect future events or developments.

Contact:
Amazing Energy Oil & Gas Co.
Terry Dunne, (509) 462-0315
Chairman and CEO
Terry@amazingenergy.com




CONTACT: Amazing Energy Oil & Gas Co.
Terry Dunne, 509-462-0315
Chairman and CEO
Terry@amazingenergy.com

Source: Amazing Energy Oil and Gas Co.

I've been watching this for a couple of months and bought my first shares today. It's an interesting story to say the least.

Does anyone have a copy of Time and Sales from Thursday?

Once this seller has exhausted their supply it shouldn't be long before we can start a new sustained move to the old highs. It's impossible to know when that will be, but as anxious as they seem to be to dump their shares I don't think it will be much longer.

Usually you can miss day in this stock and not miss much. Obviously not so yesterday. While I'm disappointed we've reached this level I am comfortable buying down here. Technically it's weak but I feel strongly we'll recover and meet the necessary .10 target. We can buy a lot more shares at .02 than we can at .03.

I'm comfortable with that chart. There is an active seller in the market at this time but I can't see them holding the price down much longer. Once they are done fumbling around and learning how to sell stock we should have an easy time recovering.

I bought heavily over the past week without much resistance. Now that we have hit .03, however, there appears to a be a more aggressive seller coming at us. No worries. I'm speculating here, but I think a long term holder is selling into this recovery from last months sell off. It could also be the party that paid for the promotion bailing on more. It's really impossible to know for sure with the limited info we have. While they do what they do I'll just keep chipping away.

Eventually the sellers will run out of stock or simply give up and we'll break through .03 and on to new highs. We're at a place where the company has established a range and the next wave of developments will fuel us higher.

Remember, too, this is also one of the lightest volume periods of the year as we move into the long U.S. holiday weekend.

Time for Fast Money, and Amanda Drury looks hot in that red dress....

Trade on!

Sort of like short covering.... I bought back 1,000,000 today of the 2.1 million I sold, and still have enough powder left to buy 2 million.

17 minutes after I posted yesterday I received a call from Michael Hayes. We spoke for 33 minutes and I have to say I am pleased and impressed with the answers I received.

Yes, my questions are about the right of first refusal to the restricted shares. One of the top risks a stock like this faces is dilution. For 25 years I've heard all the promises of holding the restricted shares, being in it for the long term, and that they are never going to hit the street. Most of the time it's a line of BS. I said MOST of the time. So in this case I want a little further explanation above and beyond the twitters, PR, and conference calls. Michael delivered. I am confident that he has the commitments in place, solidly, to prevent those shares from getting to the street prematurely. This is my greatest concern with the stock, and he addressed it to my satisfaction.

Michael and I discussed the recent paid campaign by a non-affiliated stockholder. I think the recent decline is largely the result of that paid promotional campaign. I have been watching closely to see if that selling barrage is waning or completely over. Based on the tape, and what Michael told me about his intervention to put a stop to campaigns like that, I believe that selling pressure is behind us. There is enough volume in EPGL to build a good useful technical chart and I think the chart further supports the position that the selling campaign is done.

We also discussed the fact that he put together a conference call to address shareholder concerns and that out of over 20 callers only 3 identified themselves and participated. If you have an opinion or question that you think is important enough to post here, it's also important enough to be discussed in a conference call. Hiding behind the anonymity of a message board to bash any stock is lame.

This has been a long and complicated restructuring and Michael has done a very professional job of getting the company and the stock to where it is. When I bought from 2009-2011 I made a prediction of where the stock could go and it hit exactly the mark. So now that the initial targets have been hit I have to assess the possibilities for further gains and trade appropriately.

In the past 2 months I sold 2,110,000 at an average of .0361. That is less than 20% of my position. Most of that was sold in March so I had no influence on the recent decline. After talking with Michael yesterday I am beginning to buy that back. Considering the current price I could even buy 50% more than the position I sold.

I am bullish on EPGL and will continually assess and consider the actions of the company and the stock, as everyone should.

But hey, I could be wrong.

Another day with no response from the company. As the person who PM'd me pointed out, the company may be uninterested in discussing anything they deem unfriendly or unsupportive. I am tending to agree.

I am glad you had success communicating with EPGL. I have sent email and left phone messages but have yet to receive a reply.

I emailed the company on Wednesday and asked about the terms of the right of first refusal that EPGL has on the PWC shares. I have not received a reply. I'll call them today to inquire directly.

You are correct. I think any of us who were buying back then were aware that the company was looking at strategic options for the future. The medical device was one of those options. I always felt that if they cleaned it up right it could be a big turn around. I still feel that way.

They are capitalized for emphasis. The shares are outstanding and will inevitably be eligible for free trading. The holders of those shares can choose to sell them if they wish. It is something that has to be considered.

Yes, the discussion has been had on this board and thousands of others about promises of restricted shares that won't be sold. Management may have the best intentions for those shares, but it may not ultimately be up to them.

Again, I see more positives than negatives in EPGL, which is why I bought from 2009 to 2011, and have only very recently sold a small percentage. However, billions and billions of restricted shares are a heavy overhang for any stock.

I've tendered restricted certs and it is not difficult. No research necessary.

Those restricted certs WILL be eligible to be tendered for free trading shares. The holder of those shares may CHOOSE not to sell them when eligible, but the fact is they can. Therefore we have to count them as if they are. That is why market cap is calculated for an individual stock using the o/s, not the float.

I hope you are right and they are responsible when it's time for those shares to be free. The fact is though they may not have any control over all of those shares and when they get sold. I like a lot of things this company is doing and I see more reasons to be positive than negative, but a large amount of shares looming behind a restriction a risk a penny stock investor has to consider.

The Dow and S&P use of free float method is for the calculation of indexes. It makes a huge difference in the calculation and volatility of indexes. It it misleading to use it for the evaluation of an individual stock. That is especially true in this case where the float is only about 10% of the outstanding. It has to be assumed that all shares, including restricted, will eventually be available and in the float.

There are a lot of positives here but as with any micro-cap it is difficult to impossible to know if what we have is truly undervalued or not. I keep reading "massively undervalued" but there doesn't seem to be enough data to give that mantra any credibility.

There is plenty for sale to all the eager believers.

Correct, I've had no trouble selling through them. I'd rather work with a full service broker on something like this. I like where the company is going so far, but I'm closer to an exit at this point than an entrance.

I have enough and am unconcerned if I they let me buy more or not. I'm a net seller at this point. I'm moving what I have to a full service broker to sell, then move the proceeds back to TDA to buy bonds and write covered calls.